Rosuvastatin

SKU: orb1307792

Description

Rosuvastatin

Research Area

Cell Biology, Infectious Disease & Virology, Metabolism Research, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 287714-41-4
• MW: 481.54
• Purity: 99.95%
• Formula: C₂₂H₂₈FN₃O₆S
• SMILES: CC(C)c1nc(nc(-c2ccc(F)cc2)c1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)N(C)S(C)(=O)=O
• Target: HMG-CoA Reductase,Antibacterial,Potassium Channel,Autophagy
• Solubility: H2O:1 mg/mL (2.08 mM);DMSO:50 mg/mL (103.83 mM)

Bioactivity

• Target IC50:
  HMG-CoA:11 nM
• In Vivo:
  METHODS: To investigate the anti-atherosclerotic effects, Rosuvastatin (5 mg/kg) and candesartan (2.5 mg/kg) were administered by gavage to streptozotocin-induced diabetic Apoe-/- mice once daily for 20 weeks. RESULTS: In the absence of lipid-lowering effects, Rosuvastatin attenuated plaque area in diabetic mice.The anti-atherosclerotic effect of Rosuvastatin was comparable to that of candesartan. Dual therapy had similar beneficial effects, although it was not superior to monotherapy.
• In Vitro:
  METHODS: Microglia cultures subDIV were treated with Rosuvastatin (1 µM) and LPS (20 ng/mL) for 24 h, and cell counts were measured by Bürker chamber. RESULTS: After the 24 h treatment period, Rosuvastatin significantly inhibited cell proliferation in unchallenged and LPS-challenged cultures by 47.8% and 68.9%, respectively. METHODS: Nthy-ori 3-1 and B-CPAP cells were treated with Rosuvastatin (12.5-200 µM) for 48-72 h. Apoptosis was detected by TUNEL assay. RESULTS: The number of apoptotic cells increased in both Nthy ori 3-1 and B-CPAP cells after Rosuvastatin treatment. 12.5 µM concentration of Rosuvastatin treatment resulted in an increase in Apoptotic Index of Nthy ori 3-1 and B-CPAP cells after 48 h. The results were summarized as follows.

Storage & Handling

• Storage: keep away from moisture,store at low temperature,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

QTc, Potassium Channel, PotassiumChannel, potential, ZD 4522, ZD4522, ZD-4522, Rosuvastatin, related, repolarization, triglycerides, action, APDs, Autophagy, durations, cholesterol, cardiac, KcsA, Inhibitor, inhibit, lipoprotein, low-density, hERG, gene, HMGCR, HMGCoAReductase, HMG-CoA Reductase (HMGCR), HMG-CoA reductase, HMGCoA Reductase, Hsp70

Compound Identifiers

PubChem CID

446157